Menu Back toSession 10 Track 1 and 2 – Alternative Approaches to Other Extrahepatic Delivery

DIA/FDA Oligonucleotide-Based Therapeutics Conference

DIA Your Way! Join us live in-person or live from the comfort of your home/office. This event offers two learning avenues depending on your preference!


Session 10 Track 1 and 2 – Alternative Approaches to Other Extrahepatic Delivery

Session Chair(s)

Andrew  Slugg, MBA, MS

Andrew Slugg, MBA, MS

  • Senior Vice President, Global Head of Regulatory Affairs
  • Alnylam Pharmaceuticals, United States
Elena  Braithwaite, PhD

Elena Braithwaite, PhD

  • Toxicologist
  • FDA, United States
Targeted delivery of oligonucleotide-based therapeutics allows for the possibility of unlocking previously inaccessible targets, enhancing target engagement leading to increased therapeutic outcomes with reduced doses and the potential for fewer off-target effects. This session will discuss a number of emerging novel targeting and delivery strategies for increasing productive uptake into a variety of cell types that normally are challenging to reach with oligonucleotide therapeutics.
Learning Objective : At the conclusion of this session, participants should be able to:
  • Identify multiple emerging novel targeting strategies for oligonucleotides
  • Discuss different strategies for targeting novel cell-types with oligonucleotides
  • Contrast the development challenges and opportunities of a variety of emerging novel targeting strategies for oligonucleotides

Speaker(s)

Arthur A. Levin, PhD

Speaker

Arthur A. Levin, PhD

  • CSO
  • Avidity Biosciences , United States
Robert  MacLeod, PhD

Speaker

Robert MacLeod, PhD

  • Chief Scientific Officer, SVP Research and Development
  • Flamingo Therapeutics, Belgium
Daniel J. Siegwart, PhD, MS

Speaker

Daniel J. Siegwart, PhD, MS

  • Associate Professor, Department of Biochemistry, SCCC
  • University of Texas Southwestern Medical Center, United States